Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for active immunotherapy as well as disease prevention. 

In contrast to traditional therapies, the goal of active immunotherapy is to amplify the patients’ ability to fight specific disease rather than targeting the diseased tissue or pathogenic agent directly.  The novel technologies being developed at Antigen Express allows for robust and antigen-specific stimulation of CD4+ T cells, a cell type critical in the recognition of pathogens and modulation of the immune response. 

Antigen Express is developing these technologies for application to the treatment of cancer, infectious diseases, and other serious diseases.  Our most advanced vaccine utilizes a self-potentiating peptide as an off-the-shelf product for active immunotherapy of breast and prostate cancer. 




  ASCO: AE37 Peptide Vaccine May Help Prevent Breast Cancer Recurrence




»read more about us


10/21/2014   Generex Announces Publication of Ebola Vaccine White Paper by Antigen Express
10/7/2014   Generex Clarifies Utility of Antigen Express Technology for Potential Ebola Vaccine
9/3/2014   Generex / Antigen Express to Participate in BioPharm America™ 2014

Dr. Elizabeth Mittendorf ASCO 2014

Primary Analysis of AE37 Vaccine in Breast Cancer

From ASCO 2014, Elizabeth A. Mittendorf, M.D., Ph.D., an Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center discusses the primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.

Interview from the JP Morgan Conference 2014 - Dr. Eric von Hofe

© 2004 Antigen Express | One Innovation Drive | Worcester, MA 01605
Phone: (508) 852-8783 | Fax: (508) 852 8653 |
Website designed by NRG Networks